Clinical Trial Update: Phase III Clinical Trial to Evaluate the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula Polymorpha) [Phase 3]

View source ↗

Summary

Phase III trial evaluating a recombinant human norovirus bivalent GI.1/GII.4 vaccine completed, sponsored by the National Vaccine and Serum Institute in China, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Norovirus Infection
• Norwalk Gastroenteritis

Drugs mentioned

• Human Norovirus Bivalent GI.1/GII.4 Recombinant Vaccine (Norovirus vaccine (GI.1/GII.4))

Snippet

Sponsor: National Vaccine and Serum Institute, China | Conditions: Norovirus Infections, Norwalk Gastroenteritis | Phase 3 | Status: COMPLETED